OTLK

Outlook Therapeutics (OTLK)

About Outlook Therapeutics (OTLK)

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Details

Daily high

$0.22

Daily low

$0.16

Price at open

$0.22

52 Week High

$3.39

52 Week Low

$0.16

Market cap

26.6M

Dividend yield

0.00%

Volume

24.2M

Avg. volume

1.3M

P/E ratio

-.29

Outlook Therapeutics News

Details

Daily high

$0.22

Daily low

$0.16

Price at open

$0.22

52 Week High

$3.39

52 Week Low

$0.16

Market cap

26.6M

Dividend yield

0.00%

Volume

24.2M

Avg. volume

1.3M

P/E ratio

-.29